Allianz’s Vertex Pharmaceuticals VRTX Stock Holding History

Allianz’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.7M	Sell	23,921 -1,260	-5%	-$588K	0.12%	104
2025 Q4	$11.4M	Buy	25,181 +1,260	+5%	+$543K	0.15%	84
2025 Q3	$9.37M	Sell	23,921 -14	-0.1%	-$5.85K	0.2%	90
2025 Q2	$10.7M	Sell	23,935 -12	-0.1%	-$5.53K	0.25%	77
2025 Q1	$11.6M	Sell	23,947 -54	-0.2%	-$25.2K	0.31%	66
2024 Q4	$9.58M	Sell	24,001 -2,088	-8%	-$968K	0.25%	81
2024 Q3	$12.1M	Buy	26,089 +1,777	+7%	+$854K	0.33%	66
2024 Q2	$11.4M	Sell	24,312 -1,660	-6%	-$721K	0.33%	59
2024 Q1	$10.9M	Buy	+25,972	New	+$11M	0.34%	66

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Allianz's VRTX Position: Q1 2026 in Review

Allianz reduced its Vertex Pharmaceuticals (VRTX) stake by 5% in Q1 2026, selling an estimated $588K and leaving 23,921 shares worth $10.7M. The position accounts for 0.12% of the portfolio, ranked #104.

Allianz first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $12.1M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Allianz held 23,921 shares of Vertex Pharmaceuticals worth $10.7M as of Q1 2026.
Allianz sold 1,260 Vertex Pharmaceuticals shares in Q1 2026, an estimated $588K.
Vertex Pharmaceuticals made up 0.12% of Allianz's portfolio in Q1 2026, its #104 holding.
Allianz first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Allianz's Vertex Pharmaceuticals position peaked at $12.1M in Q3 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Allianz's 13F filing for Q1 2026, filed 11 May 2026.